Loading the company…
Loading the company…
In the last ten years FDA made 2 decisions for Novapproach Spine (510(k) clearances, De Novo grants, PMA approvals and supplements) under the product codes MedaRep maps to 1 procedure family, the most in 2025 (1). The latest was on 2025-06-12.
| Family | Decisions on record |
|---|---|
| Lumbar fusion | 2 |
| Date | Kind | Number | Device |
|---|---|---|---|
| 2025-06-12 | 510(k) | K251459 | OneLIF Interbody Fusion System |
| 2021-09-07 | 510(k) | K211769 | OneLIF Intervertebral Body Replacement System |
Decisions under the product codes mapped to the procedure families; devices filed under other codes are not here. Applicants are rolled up to Novapproach Spine.
In 2025, Novapproach Spine reported engagement with 28 surgeons and other clinicians in the states MedaRep covers, worth $33K in consulting, speaking, meals and travel for its device products, the most in Michigan ($17K to 3). Royalties are left out.
Spend tied to a procedure counts the payments whose product names it. Open Payments shows the payments companies reported. It suggests engagement, not which devices a surgeon uses, and is not evidence of wrongdoing.Top states by spend: Michigan ($17K, 3 engaged), Florida ($12K, 5 engaged), California ($2,566, 2 engaged), Texas ($605, 6 engaged), Alabama ($406, 3 engaged).